This excerpt taken from the ABII 8-K filed Nov 8, 2007.
In June 2005, ABI entered into a two-year, $200.0 million credit facility secured by certain of ABIs assets. On March 6, 2006, ABI amended its $200.0 million credit facility to increase the allowed borrowings to $215.0 million. At December 31, 2005, $190.0 million was outstanding under the facility. On April 18, 2006, $214.0 million was outstanding under the facility, which was paid off in connection with the closing of the 2006 Merger. No amounts were outstanding under the facility at December 31, 2006. New Abraxis incurred $0.5 million in fees in connection with the facility, which were being amortized over the facilitys two-year term and the $0.3 million of unamortized debt acquisition costs were written off in conjunction with the closing of the 2006 Merger in the second quarter of 2006. In connection with the closing of the 2006 Merger, the prior credit facility was replaced with an Abraxis BioScience three-year, $450 million, unsecured credit facility.